These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 11900092)
1. Medical technology's impacts and costs. Christian J; Weissberg J Health Aff (Millwood); 2002; 21(1):276-7. PubMed ID: 11900092 [No Abstract] [Full Text] [Related]
2. ICER's Revised Value Assessment Framework for 2017-2019: A Critique. Neumann PJ; Cohen JT Pharmacoeconomics; 2017 Oct; 35(10):977-980. PubMed ID: 28791663 [No Abstract] [Full Text] [Related]
3. Comment on: 'The cost of a QALY'. Adam J; Stevens A QJM; 2011 Mar; 104(3):272-3. PubMed ID: 21030464 [No Abstract] [Full Text] [Related]
4. The importance of subjective values to medical technology assessment and health policy. Diamond GA J Invasive Cardiol; 1993; 5(1):17-22. PubMed ID: 10148297 [No Abstract] [Full Text] [Related]
5. Prospective value-based assessment of new health care technologies and practices. Girod CS; Axene DV Manag Care; 2000 Aug; 9(8):38-40, 43-7. PubMed ID: 11186514 [No Abstract] [Full Text] [Related]
6. [Evaluation of medical methods--can we rely on cost-benefit-analysis?]. Kristiansen IS; Stavem K; Linnestad K; Pedersen KM Tidsskr Nor Laegeforen; 2003 Mar; 123(5):657-60. PubMed ID: 12683199 [No Abstract] [Full Text] [Related]
8. The economic value of medical technology. Gandjour A Health Aff (Millwood); 2002; 21(1):275-6. PubMed ID: 11900091 [No Abstract] [Full Text] [Related]
10. Economic evaluation and the postponement of health care costs. van Baal PH; Feenstra TL; Polder JJ; Hoogenveen RT; Brouwer WB Health Econ; 2011 Apr; 20(4):432-45. PubMed ID: 21210494 [TBL] [Abstract][Full Text] [Related]
11. Could or Should We Use MCDA in the French HTA Process? Ghabri S; Josselin JM; Le Maux B Pharmacoeconomics; 2019 Dec; 37(12):1417-1419. PubMed ID: 31565761 [No Abstract] [Full Text] [Related]
12. The impact of technology on health care costs. Cotterill PG Profile Med Pract; 1980; ():107-21. PubMed ID: 10309443 [No Abstract] [Full Text] [Related]
13. A review of the use of health status measures in economic evaluation. Brazier J; Deverill M; Green C; Harper R; Booth A Health Technol Assess; 1999; 3(9):i-iv, 1-164. PubMed ID: 10392311 [No Abstract] [Full Text] [Related]
14. Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. Morton A; Adler AI; Bell D; Briggs A; Brouwer W; Claxton K; Craig N; Fischer A; McGregor P; van Baal P Health Econ; 2016 Aug; 25(8):933-8. PubMed ID: 27374115 [TBL] [Abstract][Full Text] [Related]
15. Economic evaluation for pharmaceuticals in Germany. Jönsson B Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033 [No Abstract] [Full Text] [Related]
16. Managed care in the Organization for Economic Cooperation and Development countries: prospects for quality, effectiveness, and equity. Nolan B Health Care Manag; 1995 Oct; 2(1):125-42. PubMed ID: 10165627 [TBL] [Abstract][Full Text] [Related]
17. Technology framework. A system's five-phase approach integrates values with vision. Stempien TL Health Prog; 1993; 74(1):58-62. PubMed ID: 10123572 [TBL] [Abstract][Full Text] [Related]
18. The cost of a QALY. Kirkdale R; Krell J; Brown CO; Tuthill M; Waxman J QJM; 2010 Sep; 103(9):715-20. PubMed ID: 20519275 [TBL] [Abstract][Full Text] [Related]
19. Analysis of regional data. Costs vs. benefits of ALS. Scheib BT JEMS; 1983 Jan; 8(1):79-82. PubMed ID: 10309829 [No Abstract] [Full Text] [Related]
20. NICE and new: appraising innovation. Ferner RE; Hughes DA; Aronson JK BMJ; 2010 Jan; 340():b5493. PubMed ID: 20051468 [No Abstract] [Full Text] [Related] [Next] [New Search]